Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Androgen Resistant Metastatic Prostate Cancer
|ClinicalTrials.gov Identifier: NCT01278914|
Recruitment Status : Completed
First Posted : January 19, 2011
Last Update Posted : July 22, 2011
Determination of safety and toxicity of vaccination with mRNA transfected DC (based on blood samples, and adverse events).
Determine immunological response to the vaccine (induction of specific T-cell response) and assessment of tumour response.
|Condition or disease||Intervention/treatment||Phase|
|Prostate Cancer||Biological: Dendritic Cells (DC) prostate||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||Phase I/II Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Androgen Resistant Metastatic Prostate Cancer|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01278914
|Oslo university Hospital|